Drug Trial Radar · NCT06220773
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
276
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
Conditions
- Essential Hypertension
- Type 2 Diabetes Mellitus
Interventions
BR1019ADrug
Subjects take the investigational products once a day for 12 weeks.
BR1019BDrug
Subjects take the investigational products once a day for 12 weeks.
BR1019CDrug
Subjects take the investigational products once a day for 12 weeks.
BR1019A-1Drug
Subjects take the investigational products once a day for 12 weeks.
BR1019B-1Drug
Subjects take the investigational products once a day for 12 weeks.
BR1019C-1Drug
Subjects take the investigational products once a day for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of mean sitting systolic blood pressure from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A-1+BR1019B+BR1019C-1Time frame: 12 weeks from Baseline Visit
- The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1Time frame: 12 weeks from Baseline Visit
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD)
Jakarta, DKI Jakarta, Indonesia · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.